Achieving a better cure for cancer

More info


CiMaas develops immunotherapy for cancer by optimally engaging the immune system.

Read more about CiMaas Immunotherapy products,
or watch our video.

News /

CiMaas to present at Biotech Showcase 2023

CiMaas BV, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary NK cell expansion platform, announced the date for a presentation of the company at the Biotech Showcase 2023, the investor conference as follows: Monday, January 09, 2023, at 3:00PM at the Hilton San Francisco - Union Square, 333 O'Farrell Street, Ballroom Level San Francisco, CA 94102, USA.

News /

CiMaas reaches next milestone in NK cell expansion and function

CiMaas successfully expands Natural Killer (NK) cells to clinically relevant numbers using a 2-week protocol. Starting from 200 ml peripheral blood, NK are expanded to numbers meeting the expected clinically required 10.E8 cells/kg, with multiple infusions. This makes the expansion method developed directly applicable for clinical application of the produced NK cells in anti-cancer therapies.